Patent ID: 11883402
Assignee: SPECTRUM PHARMACEUTICALS, INC.
Field: Pharmaceuticals (Chemistry)
Classification: CPC A  C | IPC A  C

Claim 0:
1. Crystalline form of a compound of Chemical formula (1):, wherein the chemical purity of the crystalline form is greater than about 80%, and
wherein the crystalline form is selected from the group consisting of
(a) a dihydrate (2H2O) crystalline form of the compound of Chemical Formula (1) and the crystalline form, wherein the dihydrate crystalline form has an X-ray powder diffraction (XRPD) pattern comprising peaks at diffraction angle 2θ values of 9.4°±0.2°, 13.0°±0.2° and 18.5°±0.2° when irradiated with a Cu-Kα light source;
(b) an anhydrous Form I of the compound of Chemical Formula (1), wherein the anhydrous Form I has an XRPD pattern comprising peaks at diffraction angle 2 values θ of 6.0°±0.2°, 18.3°±0.2° and 22.7°±0.2° when irradiated with a Cu-Kα light source;
(c) an anhydrous Form II of the compound of Chemical Formula (1), wherein the anhydrous Form II has an XRPD pattern comprising peaks at diffraction angle 20 values of 4.9°±0.2°, 5.9°±0.2° and 11.8°±0.2° when irradiated with a Cu-Kα light source;
(d) a monohydrochloride monohydrate (1HCl·1H2O) crystalline form of the compound of Chemical Formula (1), wherein the monohydrochloride monohydrate crystalline form has an XRPD pattern comprising peaks at diffraction angle 2θ values of 8.9°±0.2°, 13.4°±0.2°, 21.1°±0.2° and 23.5°±0.2° when irradiated with a Cu-Kα light source; and
(e) an anhydrous monohydrochloride crystalline form of the compound of Chemical Formula (1), wherein the anhydrous monohydrochloride crystalline form has an XRPD pattern comprising peaks at diffraction angle 2 values θ of 9.5°±0.2°, 23.0°±0.2°, 23.2°±0.2° and 23.5°±0.2° when irradiated with a Cu-Kα light source.